Barclays Forecasts Strong Price Appreciation for Pacira BioSciences (NASDAQ:PCRX) Stock

Pacira BioSciences (NASDAQ:PCRX) had its target price lifted by Barclays from $17.00 to $24.00 in a report issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price target indicates a potential downside of 0.21% from the company’s current price.

Other research analysts have also issued research reports about the company. HC Wainwright lifted their target price on Pacira BioSciences from $57.00 to $70.00 and gave the company a “buy” rating in a report on Friday. Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their target price for the company from $8.00 to $25.00 in a report on Thursday, January 30th. Royal Bank of Canada reiterated a “sector perform” rating and set a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Finally, Needham & Company LLC lifted their price target on Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Friday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $27.22.

Pacira BioSciences Trading Down 5.2 %

Shares of PCRX opened at $24.05 on Friday. The business has a 50-day moving average of $23.16 and a 200 day moving average of $18.63. Pacira BioSciences has a fifty-two week low of $11.16 and a fifty-two week high of $31.67. The firm has a market cap of $1.11 billion, a P/E ratio of -11.85 and a beta of 0.80. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25.

Institutional Trading of Pacira BioSciences

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Sterling Capital Management LLC increased its stake in shares of Pacira BioSciences by 779.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock valued at $26,000 after buying an additional 1,208 shares during the period. Ancora Advisors LLC purchased a new stake in Pacira BioSciences in the fourth quarter worth $26,000. Caitlin John LLC grew its stake in Pacira BioSciences by 1,850.0% in the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock worth $35,000 after purchasing an additional 1,776 shares during the period. Nisa Investment Advisors LLC grew its stake in Pacira BioSciences by 495.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after purchasing an additional 2,749 shares during the period. Finally, PNC Financial Services Group Inc. grew its stake in Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock worth $68,000 after purchasing an additional 513 shares during the period. Institutional investors own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.